NewcelX Ltd NCEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 5.78M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 4.20
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 4
- Website
- https://www.newcelx.com
Valuation
|
Metric
|
NCEL
|
|---|---|
Price/Earnings (Normalized) | 4.20 |
Price/Book Value | 2.37 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NCEL
Financial Strength
|
Metric
|
NCEL
|
|---|---|
Quick Ratio | 0.19 |
Current Ratio | 0.40 |
Interest Coverage | — |
Quick Ratio
NCEL
Profitability
|
Metric
|
NCEL
|
|---|---|
Return on Assets (Normalized) | 7.99% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −644.59% |
Return on Assets
NCEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|x<C&jg | LOCK|%ZG^ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|zL$>&G? | LOCK|%!yL | $83B | |||
| Moderna Inc
MRNA
| LOCK|^?Dj#?Q | LOCK|Syn | $80B | |||
| argenx SE ADR
ARGX
| LOCK|ZgmQ<D | LOCK|^! | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|fx&K@J | LOCK|h@ | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$jKXk#@ | LOCK|BlRrC | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|##y<v#Y# | LOCK|Gds@ | $28B | |||
| Incyte Corp
INCY
| LOCK|d&r>rNn | LOCK|PlC | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|XpgfF#g | LOCK|@x | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Bty$^Wt | LOCK|sd | $14B |
United States